Stuart Wasser, MD
Internal Medicine · West Babylon, NYNPI 1922099852
Payments from drug & device makers
Across 409 payments — averaging $174.68 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Indivior Inc.$58K
- Idorsia Pharmaceuticals US Inc$9K
- Novo Nordisk$563
- Alkermes, Inc.$522
- Ironshore Pharmaceuticals Inc.$510
- Braeburn Inc.$501
- plus $2K from 25 others
What the payments were for
- Speaking & faculty fees$8,07260%
- Travel & lodging$1441%
- Food & beverage$4,98937%
- Education$1791%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Indivior Inc. | 159 | $58,375 |
| Idorsia Pharmaceuticals US Inc | 18 | $8,717 |
| Novo Nordisk | 22 | $563 |
| Alkermes, Inc. | 25 | $522 |
| Ironshore Pharmaceuticals Inc. | 28 | $510 |
| Braeburn Inc. | 14 | $501 |
| Orexo US, Inc. | 28 | $289 |
| AbbVie(2 entities) | 14 | $283 |
| Lundbeck LLC | 12 | $259 |
| Merck | 13 | $223 |
| USWM, LLC | 23 | $190 |
| Axsome Therapeutics, Inc. | 3 | $170 |
| MDD US Operations, LLC | 15 | $154 |
| Otsuka America Pharmaceutical, Inc. | 6 | $113 |
| Lilly USA, LLC | 4 | $80 |
| Eisai Inc. | 4 | $70 |
| Takeda Pharmaceuticals U.S.A., Inc. | 3 | $57 |
| Scilex Pharmaceuticals Inc. | 3 | $53 |
| Renalytix AI, Inc. | 2 | $47 |
| Teva Pharmaceuticals USA, Inc. | 2 | $39 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 1 | $27 |
| Exact Sciences | 1 | $26 |
| Shire North American Group Inc | 1 | $25 |
| Corium, LLC | 1 | $24 |
| Arbor Pharmaceuticals, Inc. | 1 | $23 |
| GSK | 1 | $22 |
| Sanofi-aventis U.S. LLC | 1 | $20 |
| Circassia Inc. | 1 | $18 |
| Kowa Pharmaceuticals America, Inc. | 1 | $17 |
| Metacel Pharmaceuticals LLC | 1 | $15 |
| Amgen | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$71,444 in reported general payments places this provider in the 95th percentile of 9,771 internal medicine providers in New York.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| VivitrolNaltrexone Microspheres | 55 | $84,361 |
| Buprenorphine-NaloxoneBuprenorphine Hcl/Naloxone Hcl | 311 | $53,854 |
| JardianceEmpagliflozin | 28 | $32,357 |
| MounjaroTirzepatide | 22 | $23,085 |
| OzempicSemaglutide | 21 | $19,135 |
| ZubsolvBuprenorphine Hcl/Naloxone Hcl | 39 | $17,179 |
| BelsomraSuvorexant | 37 | $16,527 |
| Buprenorphine Hcl | 210 | $7,908 |
| TrintellixVortioxetine Hydrobromide | 12 | $5,310 |
| Sumatriptan Succinate | 14 | $3,122 |
| Gabapentin | 145 | $2,035 |
| Naltrexone Hcl | 41 | $1,760 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 14 | $1,474 |
| Rosuvastatin Calcium | 86 | $1,206 |
| Nano 2nd Gen Pen NeedlePen Needle, Diabetic | 20 | $1,042 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Alkermes, Inc.Vivitrol | $522 | $84,36155 claims |
| Lilly USA, LLCMounjaro, Olanzapine | $80 | $23,50854 claims |
| Novo NordiskOzempic | $563 | $19,13521 claims |
| Orexo US, Inc.Zubsolv | $289 | $17,17939 claims |
| MerckBelsomra | $223 | $16,52737 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Trintellix | $57 | $5,31012 claims |
| AbbVieSynthroid | $283 | $88314 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 9,771 internal medicine providers in New York.
Other internal medicine in West Babylon
- Helena YuNew York$50.9M
- Neha KordeNew York$21.2M
- Karen AutioNew York$18.5M
- Ingo MellinghoffNew York$16.1M
- Gopakumar IyerNew York$12.4M
- David DoveEast Hampton$12.3M
- Robert CupeloEast Syracuse$10.6M
- Patrick ReaganRochester$9.4M
- Sally LauNew York$8.4M
- Angela BrancheRochester$7.9M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.